European infrastructure for translational medicine
Translational research is a highly multi-disciplinary and complex undertaking. As a consequence, a major challenge in developing new innovations is understanding what steps need to be taken, and what expertise and technologies are suitable to perform these steps. Researchers in need of specialised support can approach EATRIS to provide guidance in the steps to be taken, by means of clinical, biological and technological expertise available within the infrastructure. Subsequently, EATRIS will match the need with the capabilities within the infrastructure. In this way, EATRIS facilitates collaboration among academics, physicians, and developers.
EATRIS helps you de-risk and add value to your drug, vaccine or diagnostic development programme.
We do this by providing fast, tailored access to cutting-edge enabling technologies in translational research.
EATRIS is an ERIC
EATRIS is a non-profit European Research Infrastructure Consortium (ERIC). This specific legal form is designed to facilitate the joint establishment and operation of research infrastructures of European interest. EATRIS’s organisational model is based on country membership. Our institutions are selected within each country on the basis of their track record in public-private collaboration in the translational development and their multidisciplinary teams of leading academic experts, high-end research facilities, production laboratories and licenses.
EATRIS focuses on preclinical and early clinical development of drugs, vaccines and diagnostics. Solutions are provided in the fields of advanced therapy medicinal products, biomarkers, imaging and tracing, small molecules and vaccines.
The wide-ranging services portfolio focuses on supporting early decision-making and de-risking of projects.
Examples include validation and development of in vitro and in vivo biomarkers for patient stratification, molecular imaging tracers for drug development programmes, GMP manufacturing of cellular therapy products, patient-derived xenograft models, and many more highly specialised capabilities.